Tag: renal biomarkers market segments

Uncover key drivers, emerging technologies, and competitive movements shaping the biomarkers market from 2026–2035 with trusted insights from The Business Research Company

How much is the Biomarkers Market valued at in 2026, and what valuation is forecast for 2030?

The biomarkers market has seen rapid expansion in recent years. Its value is anticipated to rise from $77.42 billion in 2025 to $88.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.2%. The factors contributing to its past growth include advancements in molecular biology, increased spending on pharmaceutical research and development, a rising prevalence of cancer, more extensive use in clinical trials, and the demand for targeted therapies.

The biomarkers market is projected to experience substantial expansion over the coming years, with its size set to reach $150.52 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.2%. This anticipated growth is largely due to factors such as the broadening of personalized treatment strategies, increasing acceptance of liquid biopsy biomarkers, enhanced regulatory backing for biomarker-centric medications, advancements in neurological disease studies, and growing partnerships between pharmaceutical and diagnostic companies. Key developments expected during this period involve the rising application of biomarkers in precision medicine, their deeper integration into drug discovery and development processes, wider usage in managing oncology and chronic diseases, the proliferation of companion diagnostics, and a heightened emphasis on identifying diseases early.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Drivers Are Influencing The Growth Of The Biomarkers Market?

The rising incidence of heart diseases is projected to drive the expansion of the biomarkers market during the forecast period. Over recent years, there has been a significant surge in the application of biomarkers for individuals suffering from heart conditions. Presently, natriuretic peptides stand as the most frequently utilized biomarker, aiding in the diagnosis of heart failure patients. For heart failure diagnosis, biomarkers like circulating biomarkers with high sensitivity C-reactive protein are employed. In the United States, heart disease ranks among the primary causes of mortality across most racial and ethnic demographics. Consequently, the growing prevalence of heart diseases will fuel the demand for biomarkers. As an illustration, data from September 2025, provided by the British Heart Foundation, a UK-based charity, reveals that over 7.6 million people in the UK (comprising more than 4 million men and over 3.6 million women) are currently affected by cardiovascular disease. Furthermore, projections suggest that this figure could increase by approximately 1 million by 2030 and by roughly 2 million by 2040, influenced by an aging populace and better survival rates. This sustained increase in heart diseases is thus accelerating the growth of the biomarkers market.

How Is The Biomarkers Market Organized Into Various Segments?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

Which Competitive Trends Are Impacting The Structure Of The Biomarkers Market?

Major companies active in the biomarker market are creating advanced products, such as biomarker tests, to attract larger customer bases, boost sales, and increase revenue. Biomarker tests, also known as biomarker assays, are laboratory or diagnostic techniques that measure specific biological markers, including molecules, genes, proteins, or other substances, to provide information about various physiological or pathological processes within the body. For instance, in July 2023, Quest Diagnostics, a US-based medical laboratories company, launched a novel prostate cancer biomarker test. This newly introduced tissue-based test service aims to fulfill the urgent clinical need for tests capable of distinguishing potentially aggressive cases of prostate cancer in males. Quest developed and validated this laboratory test through an intellectual property license agreement with Envision, allowing the utilization of Envision’s exclusive biomarker and immunohistochemistry technology, incorporating Envision’s distinct staining methods and innovative biomarkers referred to as EV1, EV2, and EV3.

Who Are The Top-Performing Companies In The Biomarkers Market In Recent Years?

Major companies operating in the biomarkers market are Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Currently Holds The Largest Share Of The Biomarkers Market?

North America was the largest region in the biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Browse Through More Reports Similar to the Global Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the biomarkers market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Biomarkers Market Be Worth By 2029, And What CAGR Will It Achieve?

The biomarkers market has seen rapid expansion in recent years. Its value is projected to increase from $68.77 billion in 2024 to $77.42 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.6%. This historical growth is attributable to advancements in genomics and proteomics technologies, the rising prevalence of chronic diseases, a heightened focus on personalized medicine, the escalating demand for companion diagnostics, and the broadening scope of applications in drug development.

The biomarkers market is projected to experience substantial growth in the upcoming years, with its size expected to reach $131.78 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 14.2%. This anticipated expansion during the forecast period stems from factors such as an intensified focus on early disease identification and prevention, the broader application of biomarkers in oncology and immunotherapy, increasing financial commitment to precision medicine initiatives, the proliferation of liquid biopsy as a non-invasive method for biomarker detection, and the rising utilization of biomarkers in drug discovery and development. Noteworthy trends predicted for this period include the creation of multi-biomarker panels, the emergence of exosome-based biomarkers, the implementation of point-of-care biomarker testing, the integration of real-world data into biomarker research, and the exploration of microbiome-derived biomarkers.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

Which Factors Are Driving The Biomarkers Market Forward?

The surge in heart diseases is anticipated to significantly fuel the expansion of the biomarkers market throughout the projected timeframe. The application of biomarkers in patients suffering from heart disease has seen a substantial rise in recent years. At present, natriuretic peptides are the most frequently utilized biomarkers, aiding in the diagnosis of individuals with heart failure. Furthermore, circulating biomarkers, such as high sensitivity C-reactive protein, are also employed for diagnosing heart failure. Given that heart disease ranks among the primary causes of death for most racial and ethnic groups within the United States, an escalation in its prevalence will consequently boost the demand for biomarkers. For example, in August 2022, a report from the American College of Cardiology, a US-based non-profit medical association, indicated a projected increase in all four cardiovascular risk factors in the United States between 2025 and 2060. The most substantial percentage growth is predicted for diabetes, rising by 39.3% to 55 million individuals, followed by dyslipidemia, which is expected to increase by 27.6% to 126 million, hypertension by 25.1% to 162 million, and obesity by 18.3% to 126 million. Researchers also noted that the largest projected increases in cardiovascular disease rates were observed for stroke, at 33.8% to 15 million, and heart failure, at 33.4% to 13 million, with ischemic heart disease increasing by 30.7% to 29 million, and heart attack by 16.9% to 16 million. This overall increase in heart diseases and related deaths is expected to contribute to a rise in growth for biomarkers.

Which Segments Form The Key Structure Of The Biomarkers Market?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

What Strategic Shifts And Innovations Are Influencing The Biomarkers Market?

Leading companies active in the biomarker market are concentrating on developing innovative solutions, such as a new biological marker, to boost innovation through collaborative research, technology integration, and strong clinical validation. A novel biological marker is a recently identified indicator that reflects biological processes and helps in diagnosing or tracking diseases. It can manifest as a molecule, gene, or cellular characteristic with potential significance for personalized medicine. For instance, in September 2024, Genialis, a US-based computational precision medicine company, introduced a first-in-class biomarker. This biomarker significantly improves the predictive accuracy for patient responses to KRAS inhibitors, allowing for personalized treatment plans and enhanced clinical outcomes. Its extensive use across various cancer types facilitates efficient drug development and optimizes patient selection for targeted therapies.

Which Firms Are Making The Biggest Impact In The Biomarkers Market?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Is Expected To Lead The Biomarkers Market In The Next Few Years?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Browse Through More Reports Similar to the Global Biomarkers Market 2025, By The Business Research Company

Small Animal Imaging In Vivo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-animal-imaging-in-vivo-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Biologics Market 2025

https://www.thebusinessresearchcompany.com/report/biologics-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Biomarkers Market Expected To Expand Between 2025 And 2029?

The biomarkers market has observed substantial growth recently. It is set to expand from $68.77 billion in 2024 to $77.42 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.6%. This growth experienced in prior periods can be attributed to several factors including advancements in genomics and proteomics technologies, a rise in the prevalence of chronic diseases, an increasing emphasis on personalized medicine, a growing demand for companion diagnostics, and the expansion of applications within drug development.

The biomarkers market is projected to experience swift expansion in the coming years, anticipated to reach $131.78 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.2%. Several factors contribute to this growth during the forecast period, including an increased emphasis on early disease identification and prevention, the broader application of biomarkers in oncology and immunotherapy, greater investment in precision medicine initiatives, the emergence of liquid biopsy as a non-invasive technique for biomarker detection, and a rising inclination towards biomarkers in drug discovery and development. Key trends expected during this period encompass the creation of multi-biomarker panels, the rise of exosome-based biomarkers, the uptake of point-of-care biomarker testing, the incorporation of real-world data into biomarker research, and the investigation of microbiome-based biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Are The Main Drivers Boosting The Biomarkers Industry’s Expansion?

The rising incidence of heart diseases is anticipated to propel the biomarkers market’s growth throughout the forecasted period. The application of biomarkers in managing patients with heart conditions has seen a significant increase over recent years. Currently, natriuretic peptides are the most commonly used biomarker, aiding in the diagnosis of heart failure patients. Furthermore, biomarkers such as circulating biomarkers with high sensitivity C-reactive protein are utilized for diagnosing heart failure. Heart disease is a leading cause of death for people across most racial and ethnic groups in the United States, and this increase in heart diseases will drive the demand for biomarkers. For instance, in August 2022, a report published by the American College of Cardiology, a US-based non-profit medical association, indicated that all four cardiovascular risk factors are expected to rise in the United States between 2025 and 2060. The largest percentage increase is projected for diabetes, with a 39.3% rise to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also observed that the most substantial projected increases in cardiovascular disease rates were for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Due to the growing prevalence of heart diseases and associated fatalities, an expansion in the biomarkers market is expected.

What Are The Major Segment Categories Driving The Biomarkers Market Growth?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

How Are Emerging Market Trends Shaping The Biomarkers Industry Landscape?

Leading companies within the biomarker market are concentrating on devising innovative solutions, like a novel biological marker, to foster innovation through cooperative research, the assimilation of technology, and thorough clinical validation. A novel biological marker represents a recently discovered indicator that mirrors biological processes and assists in the diagnosis or monitoring of diseases. It can manifest as a molecule, a gene, or a cellular trait with significant implications for personalized medicine. For instance, in September 2024, Genialis, a US-based company specializing in computational precision medicine, introduced a pioneering biomarker. This first-in-class biomarker elevates the accuracy of predictions regarding patient responses to KRAS inhibitors, thereby enabling individualized treatment strategies and enhancing clinical outcomes. Its extensive utility across diverse cancer types aids in efficient drug development and refines patient selection for targeted therapies.

Who Are The Top Performing Companies In The Biomarkers Market In Recent Years?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Regional Markets Are Contributing Most To The Biomarkers Industry Expansion?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Browse Through More Reports Similar to the Global Biomarkers Market 2025, By The Business Research Company

Small Animal Imaging In Vivo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/small-animal-imaging-in-vivo-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Biologics Market 2025

https://www.thebusinessresearchcompany.com/report/biologics-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Biomarkers Market Be Worth By 2029?

In recent years, the biomarkers market has experienced significant growth. The market is projected to expand from $68.77 billion in 2024 to $77.42 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. The historical growth of this market is credited to developments in genomics and proteomics technologies, rising chronic disease occurrences, increased focus on personalized medicine, a surge in companion diagnostics demand, and wider application in drug development.

The biomarkers market is anticipated to experience accelerated expansion in the forthcoming years, surging to $131.78 billion by 2029 with a compound annual growth rate (CAGR) of 14.2%. This surge over the forecast period can be credited to the amplified focus on early detection and prevention of diseases, the widening application of biomarkers in oncology and immunotherapy, increased funding for precision medicine campaigns, the emerging prominence of liquid biopsy as a non-invasive method for detecting biomarkers, and the rising preference for biomarkers in the discovery and development of drugs. The forecast period is also expected to see significant trends such as the creation of multi-biomarker panels, the emergence of exosome-based biomarkers, the incorporation of real-world data into biomarker research, the increased adoption of point-of-care biomarker testing, and the exploration of microbiome-based biomarkers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Market Forces Are Contributing To The Growth Of The Biomarkers Market?

The surge in cardiac ailments is predicted to fuel the expansion of the biomarkers market throughout the projected period. In recent years, the application of biomarkers in treating patients with heart conditions has seen a significant rise. At present, natriuretic peptides are the most commonly utilized biomarkers, aiding in the detection of heart failure in patients. Additionally, biomarkers like circulating biomarkers with a high sensitivity C-reactive protein are employed in diagnosing heart failure. Notably, heart disease is the primary cause of mortality across most racial and ethnic groups within the United States, with the rising cardiac disease prevalence catalyzing the demand for biomarkers. For example, a report issued by the American College of Cardiology, a non-profit medical association in the U.S., in August 2022 suggests that all four cardiovascular risk factors will witness an upswing between 2025 and 2060 in the United States. The most significant escalation is predicted in diabetes, with a hike of 39.3% escalating to 55 million individuals, trailed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The report also noted the highest anticipated increases in the rate of cardiovascular diseases would occur in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million). Consequently, the surge in heart diseases and related fatalities will trigger a growth spurt in the biomarkers market.

Which Segments Define The Structure Of The Biomarkers Market?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

What Strategic Shifts And Innovations Are Influencing The Biomarkers Market?

Leading firms in the biomarker sector are concentrating on creating novel solutions such as pioneering biological indicators to boost innovation through joint research, technology assimilation and strong clinical confirmation. A pioneering biological indicator is a newly discovered marker that mirrors biological reactions and is helpful in diagnosing or observing diseases. This can be a molecule, gene, or cellular attribute with potential benefits for personalized medicine. For instance, Genialis, a US-based computational precision medicine firm, introduced a first-of-its-kind biomarker in September 2024. This first-in-class biomarker improves the predictive accuracy for responses of patients to KRAS inhibitors, facilitating tailored treatment options and enhancing clinical results. Its wide-ranging use across different types of cancer aids efficient drug evolution and refines the selection of patients for targeted treatments.

Which Firms Are Making The Biggest Impact In The Biomarkers Market?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Is Forecasted To Lead The Biomarkers Market In The Coming Years?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Biomarkers Market From 2025 to 2029?

There has been rapid growth in the size of the biomarkers market in the past few years. It is set to expand from $68.77 billion in 2024 to $77.42 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. The previously observed growth in this sector can be credited to the progress made in genomics and proteomics technologies, the rising occurrence of chronic diseases, the increased focus on personalized medicine, the growing need for companion diagnostics, and the widening scope of applications in drug development.

The biomarkers industry is set for a significant expansion in the coming years, projecting to catapult to “$131.78 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 14.2%.” This anticipated growth for the forecast period is attributable to the increasing emphasis on early detection and prevention of diseases, the broadening inclusion of biomarkers in oncology and immunotherapy, and the increased funding for precision medicine initiatives. Factors like the adoption of liquid biopsy as a non-invasive way to detect biomarkers, and the growing application of biomarkers in drug discovery and development are also contributing to this growth. Key trends expected in this forecast period include the development of panels that utilize multiple biomarkers, the emergence of biomarkers based on exosomes, the widespread use of point-of-care biomarker testing, the integration of real-world data into biomarker research, and the investigation into microbiome-based biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Elements Are Contributing To Growth In The Biomarkers Market?

The rise in heart-related ailments is anticipated to fuel the expansion of the biomarkers market during the predicted timeframe. Thus, the application of biomarkers in treating heart disease patients has seen an exponential rise in recent years. Current practices reveal the natriuretic peptides as the most prevalent biomarker in diagnosing heart failure. Additionally, highly sensitive C-reactive protein, one of the circulating biomarkers, is also employed in diagnosing heart failures. Heart disease remains a leading mortality cause for most racial and ethnic groups in the United States, intensifying the demand for biomarkers. For example, a report from the American College of Cardiology in August 2022 forecasted that all four cardiovascular risk factors in the United States are set to rise between 2025 and 2060. Diabetes is projected to see the most significant leap of 39.3%, affecting 55 million people, followed by dyslipidemia with 27.6% affecting 126 million, hypertension with 25.1% affecting 162 million, and obesity with 18.3% affecting 126 million. Furthermore, the projections also highlighted stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) as the ailments with the most considerable expected increases in rates, followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Consequently, these increases in heart diseases and associated fatalities will result in a surge in the growth of the biomarkers market.

Which Segments Are Detailed In The Global Biomarkers Market Report?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

Which Emerging Trends And Strategic Shifts Are Shaping The Biomarkers Market?

Major players in the biomarker sector are zeroing in on building novel solutions, involving ground-breaking biological markers to boost innovation via concerted research, technological incorporation, and rigorous clinical confirmation. A groundbreaking biological marker is a fresh detector that signifies biological procedures and assists in detecting or supervising diseases. It could be a protein, gene, or cellular trait with latent significances for individualized medicine. To illustrate, in September 2024, Genialis, an American computational precision medicine firm, introduced a trailblazing biomarker. This marker, being the first of its kind, escalates the predictive precision for patient responses to KRAS inhibitors. This augmentation aids in delivering customized treatment schedules and enhancing the results of clinical procedures. Its wide-ranging applicability across diverse cancer forms promotes productive drug fabrication and refines patient selection for specific therapies.

Who Are The Key Contributors To Growth In The Biomarkers Market?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Is Projected To Lead The Biomarkers Market By 2025?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Does the Forecast Indicate for the Biomarkers Market From 2025 to 2029?#_x000D_

In the recent past, the size of the biomarkers market has experienced swift expansion. It is projected to escalate from a valuation of $68.77 billion in 2024 to a staggering $77.42 billion in 2025, which means a compound annual growth rate (CAGR) of 12.6%. Key factors that have driven this growth during the historical period include developments in genomics and proteomics technologies, a rising prevalence of chronic diseases, a greater focus on personalized medicine, increased demand for companion diagnostics and a broadening of their uses in the domain of drug development._x000D_

_x000D_

In the coming years, the biomarkers market is projected to experience substantial growth, expanding to an estimated $131.78 billion by 2029 with a compound annual growth rate (CAGR) of 14.2%. This expansion during the predicted period is due to an increasing emphasis on early disease diagnosis and prevention, the broadening use of biomarkers in oncology and immunotherapy, escalating investments in precision medicine programs, the emergence of liquid biopsy as a non-invasive technique for biomarker identification, and a growing preference for biomarkers in drug discovery and development. Key trends expected throughout this forecast period involve the creation of multi-biomarker panels, the rise of exosome-based biomarkers, the utilization of point-of-care biomarker testing, the integration of real-world data into biomarker research, and the exploration of microbiome-based biomarkers._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp_x000D_

_x000D_

#What Elements Are Contributing To Growth In The Biomarkers Market?#_x000D_

The escalating incidence of heart diseases is predicted to fuel the expansion of the biomarkers market in the projected timeframe. Biomarkers’ use in treating heart disease patients has seen an exceptional rise in recent times. Natriuretic peptides, as of now, are the most prevalent biomarker, assisting in the identification of individuals suffering from heart failure. Other biomarkers, like circulating ones with high sensitivity C-reactive protein, are employed for heart failure diagnoses. Heart ailments are among the primary death causes for most racial and ethnic groups in the United States, thus pushing the demand for biomarkers. As reported by the American College of Cardiology, a US-based non-profit medical group, in August 2022, it is estimated that all four cardiovascular risk elements will augment between 2025 and 2060 in the United States. Diabetes is projected to see the largest percentage increase with a surge of 39.3% to 55 million cases, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The study further observed that stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) are predicted to feel the most significant increases in cardiovascular disease rates. Next in line, ischemic heart disease (30. 7% to 29 million) and heart attack (16.9% to 16 million) follow. This incline in heart diseases and corresponding mortalities will result in the growth surge for the biomarkers._x000D_

_x000D_

#Which Segments Are Detailed In The Global Biomarkers Market Report?#_x000D_

The biomarkers market covered in this report is segmented – _x000D_

_x000D_

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers_x000D_

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases_x000D_

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases_x000D_

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies_x000D_

_x000D_

Subsegments:_x000D_

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers _x000D_

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers_x000D_

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers_x000D_

_x000D_

_x000D_

#Which Emerging Trends And Strategic Shifts Are Shaping The Biomarkers Market?#_x000D_

Leading organizations in the biomarker market are concentrating on formulating unique solutions like a novel biological marker, through joint research efforts, technological amalgamation, and strong clinical verification. A novel biological marker is a newly recognized sign that shows biological activities and helps in identifying or tracking illnesses. It can represent a molecule, gene, or cellular attribute with prospective applications in personalized medicine. For example, Genialis, a computational precision medicine firm from the US, launched an unprecedented biomarker in September 2024. This first-of-its-kind biomarker augments predictive precision for how patients react to KRAS inhibitors, facilitating tailor-made treatment plans, and enhancing clinical results. Its wide-ranging usage across multiple cancer forms accelerates effective drug creation and refines patient choice for targeted therapies._x000D_

_x000D_

#Who Are The Key Contributors To Growth In The Biomarkers Market?#_x000D_

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc. _x000D_

_x000D_

#Get The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report_x000D_

_x000D_

#Which Region Is Projected To Lead The Biomarkers Market By 2025?#_x000D_

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model